Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$56.21
−$0.55 · -0.97%
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Previous close
$56.21
−$0.55 · -0.97%
After-hours
$56.21
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Day range
Current $56.21
52-week range
Current $56.21
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
59
Fair Value
Sentiment
63
Bullish
Risk
18
Low Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Day range
Current $56.21
52-week range
Current $56.21
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF278.19M0.29%95.4B USD0.05%$233.13-0.15%
VictoryShares Free Cash Flow ETFVFLO180.92M1.58%11.19B USD0.44%$52.90+1.19%
Vanguard High Dividend Yield ETFVYM103.04M0.10%100.8B USD0.04%$158.25+0.51%
iShares Russell Mid-Cap ETFIWR97.08M0.17%55.97B USD0.18%$108.87+0.37%
Capital Group Dividend Growers ETFCGDG66.35M1.17%5.66B USD0.47%$37.25+0.24%
iShares U.S. Pharmaceuticals ETFIHE66.16M4.32%1.53B USD0.37%$98.86-0.53%
iShares Russell 1000 Value ETFIWD52.24M0.06%81.91B USD0.18%$252+0.49%
iShares MSCI USA Momentum Factor ETFMTUM37.05M0.18%20.43B USD0.15%$317.32-1.58%Vanguard Extended Market ETFVXFVictoryShares Free Cash Flow ETFVFLOVanguard High Dividend Yield ETFVYMiShares Russell Mid-Cap ETFIWRCapital Group Dividend Growers ETFCGDGiShares U.S. Pharmaceuticals ETFIHEiShares Russell 1000 Value ETFIWDiShares MSCI USA Momentum Factor ETFMTUMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
